Citadel Advisors’s Mustang Bio MBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Hold
0
-$110 14873
2023
Q1
Sell
-31
Closed -$12.7K 14582
2022
Q4
$9.24K Buy
31
+13
+72% +$4.44K ﹤0.01% 13697
2022
Q3
$6K Sell
18
-90
-83% -$41.7K ﹤0.01% 12348
2022
Q2
$47K Buy
108
+18
+20% +$9.96K ﹤0.01% 11971
2022
Q1
$68K Buy
90
+33
+58% +$27.1K ﹤0.01% 12596
2021
Q4
$71K Sell
57
-60
-51% -$96.9K ﹤0.01% 13016
2021
Q3
$236K Buy
117
+44
+60% +$94.5K ﹤0.01% 11603
2021
Q2
$183K Sell
73
-56
-43% -$137K ﹤0.01% 12263
2021
Q1
$322K Sell
129
-72
-36% -$214K ﹤0.01% 10684
2020
Q4
$570K Buy
201
+102
+103% +$244K ﹤0.01% 7902
2020
Q3
$234K Buy
99
+69
+230% +$170K ﹤0.01% 8569
2020
Q2
$72K Buy
+30
New +$70.1K ﹤0.01% 9142

Other funds holding MBIO

Citadel Advisors's MBIO Position: Q2 2026 in Review

Citadel Advisors increased its Mustang Bio (MBIO) stake by 12% in Q2 2026, buying an estimated $4.45K and bringing the position to 59,459 shares worth $41.7K. The position accounts for ﹤0.01% of the portfolio, ranked #13205.

Citadel Advisors first reported a position in MBIO in Q3 2018 and has held it in 21 quarters since. The position peaked at $679K in Q3 2020. 23 funds tracked by Wall St. Rank hold MBIO as of Q2 2026.

  • Citadel Advisors held 59,459 shares of Mustang Bio worth $41.7K as of Q2 2026.
  • Citadel Advisors bought 6,259 Mustang Bio shares in Q2 2026, an estimated $4.45K.
  • Mustang Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13205 holding.
  • Citadel Advisors first reported a position in Mustang Bio in Q3 2018 and has held it in 21 quarters since.
  • Citadel Advisors's Mustang Bio position peaked at $679K in Q3 2020.
  • 23 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.